Back to Newsroom
Back to Newsroom

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm

Monday, 24 April 2017 05:47 PM

Lundin Law PC

Topic:

LOS ANGELES, CA / ACCESSWIRE / April 24, 2017 / Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX) concerning possible violations of federal securities laws. Investors who purchased SCYNEXIS securities: (1) pursuant or traceable to the Company's initial public offering on or about May 2, 2014; and/or (2) from May 2, 2014 through March 2, 2017, inclusive (the "Class Period") should contact the firm prior to the May 8, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also do nothing and be an absent class member.

The Complaint alleges that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company's lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug's approval prospects and/or commercial viability; and as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On March 2, 2017, SCYNEXIS announced that the U.S. Food & Drug Administration "informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data" of the formulation. The hold stems from "three mild-to-moderate thrombotic events in healthy volunteers" receiving the formulation. Upon release of this news, shares of SCYNEXIS dropped in value, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/

SOURCE: Lundin Law PC

Topic:
Back to newsroom
Back to Newsroom
Share by: